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Medical Researchnowledge of the pathobiology of pulmonary hypertension (PH) continues to accelerate. However, fundamental gaps
remain in our understanding of the underlying pathological changes in pulmonary arteries and veins in the different
forms of this syndrome. Although PH primarily affects the arteries, venous disease is increasingly recognized as an
important entity. Moreover, prognosis in PH is determined largely by the status of the right ventricle, rather than the
levels of pulmonary artery pressures. It is increasingly clear that although vasospasm plays a role, PH is an
obstructive lung panvasculopathy. Disordered metabolism and mitochondrial structure, inﬂammation, and
dysregulation of growth factors lead to a proliferative, apoptosis-resistant state. These abnormalities may be
acquired, genetically mediated as a result of mutations in bone morphogenetic protein receptor-2 or activin-like
kinase-1, or epigenetically inherited (as a result of epigenetic silencing of genes such as superoxide dismutase-2).
There is a pressing need to better understand how the pathobiology leads to severe disease in some patients versus
mild PH in others. Recent recognition of a potential role of acquired abnormalities of mitochondrial metabolism in
the right ventricular myocytes and pulmonary vascular cells suggests new therapeutic approaches, diagnostic
modalities, and biomarkers. Finally, dissection of the role of pulmonary inﬂammation in the initiation and promotion
of PH has revealed a complex yet fascinating interplay with pulmonary vascular remodeling, promising to lead to
novel therapeutics and diagnostics. Emerging concepts are also relevant to the pathobiology of PH, including a role
for bone marrow and circulating progenitor cells and microribonucleic acids. Continued interest in the interface of
the genetic basis of PH and cellular and molecular pathogenetic links should further expand our understanding of
the disease. (J Am Coll Cardiol 2013;62:D4–12) ª 2013 by the American College of Cardiology FoundationThe speciﬁc ﬁeld of pathobiology of pulmonary hypertension
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D5remarkable progress, central questions remain related to the
fundamental aspects of pulmonary vascular pathology in PH.
When choosing the particular areas of emphasis in the
context of the World Symposium, the Pathology and
Pathobiology Working Group opted to continue focusing on
the pathologic alterations of pulmonary veins in PH, largely
inspired by the pressing questions in this particular area that
arose from the last worldmeeting (1). Thiswas complemented
by 3 additional topics, due to their timeliness and overall
importance: the molecular determinants of mild versus severe
PH; the role of metabolic reprogramming underlying cellular
responses in pulmonary vascular disease; and recent insights
into the role of inﬂammation as a trigger and modiﬁer of PH.
Furthermore, many pathogenetic processes operational in
mild disease appear to have roles in more severe PH, but how
molecular processes determine the progression and ultimately
the severity of the disease remains unclear. To start addressing
this complex yet central questiondperhaps one of the most
vexing challenges in the ﬁelddthe integration of pathology
and pathogenetic mechanisms should provide insights into
this topic in the years to come.
The group members acknowledge that the chosen
discussion topics did not allow for an all-inclusive dissection
of established and emerging areas of investigation. These
include, among others, speciﬁc signaling pathways shown to
affect pulmonary vasoconstriction and remodeling (such as
epidermal growth factor [4], ﬁbroblast growth factor [5],
platelet-derived growth factor [6,7], and transforming
growth factor-b [8,9]) or are protective (such as bone
morphogenetic proteins), and evolving knowledge on the
involvement of pathogenic (10) or protective (11) micro-
ribonucleic acids in pulmonary arterial hypertension (PAH).
In addition, emerging areas of investigation, including the
potential role of progenitor or stem cells in pulmonary
vascular remodeling (12), were not addressed. Notwith-
standing these limitations, when ﬁtting, we emphasize the
potential role of circulating cells derived from the bone
marrow, as documented in recent human studies (13).
Does the Pulmonary Venous System Play an
Important Role in PAH and to What Extent Are PAH
and PVOD Part of the Same Spectrum of Disease?
It is apparent that the different forms of PH present with
either a predominance of pulmonary arterial remodeling or
vein remodeling or a variable contribution of both. Para-
digmatic of the former is idiopathic pulmonary arterial
hypertension (IPAH), whereas pure pulmonary veno-
occlusive disease and PH due to left heart dysfunction
are characterized predominantly by venous remodeling.
Virtually all forms of PH, including thromboembolic PH,
sarcoid PH, and those caused by interstitial lung disease
and hypoxia, may involve elements of both arterial and
venous remodeling. However, more precise documen-
tation, including morphometric analysis of pulmonary vein
remodeling, is still lacking in most of these conditions.The difﬁculty in studying the
pathology of pulmonary venous
remodeling is compounded by the
lack of distinct molecular markers
that allow for their identiﬁcation
(as compared with the pulmonary
arterial bed) when immersed in
alveolar tissue. Normal veins can
be recognized by the lack of
a double elastic lamina and rela-
tively thin muscular media; how-
ever, when remodeled, pulmonary
veins become “arterialized,” ma-
king their distinction from pul-
monary arteries more difﬁcult.
The only distinctive feature,
which is often not present in bio-
psies, is the presence of pul-
monary veins in interlobular septae. Moreover, molecular
markers of veins, such as the ephrin B4 receptor, are often
difﬁcult to identify in human (and rat) lungs. The venous
coaxial structure includes layers of cardiomyocytes arrayed
externally around a subendothelial layer of typical smooth
muscle cells, thus forming sphincter-like structures. In disease
states, this cardiac muscle layer extends further into the lung,
and its role in Group 2 PH merits investigation.
Given the limitations in recognizing veins histologically,
most studies rely on their identiﬁcation in selected regions
of explant specimens. In subsets of PAH patients with
scleroderma-associated PAH, pulmonary veno-occlusive
disease-like remodeling may predominate over arterial
remodeling. The venous remodeling, if present, entails a
worse prognosis associated with decreased 6 min-walk
distance, partial pressure of oxygen in the blood, and
diffusion capacity (14). However, in a recent pathologic
study of PAH, including lungs with scleroderma-associated
PAH, no correlations between vein remodeling and intima
and media thickness in arteries could be identiﬁed (15).
Recent studies have highlighted the pattern of pulmonary
vein remodeling in patients with left heart failure (LHF).
Lung samples obtained from patients with LHF placed on
a ventricular assist device showed increased pulmonary vein
and artery media thickening. Of interest, some patients who
improved on the assist device and underwent repeat lung
biopsy had a signiﬁcant improvement of pulmonary vein
remodeling (16). The molecular drivers of these processes
remain largely unknown.
We continue to lack the availability of unique molecular
markers that allow the speciﬁc identiﬁcation of pulmonary
veins. Consequently, the prevalence of venous pathology in
the various forms of PH remains unknown. This is despite
the potential for deleterious effects of prostacyclin and
agents that increase bioavailability of nitric oxide in the
context of elevated capillary pressures. Finally, little is known
about pathogenetic pathways involved in pulmonary vein
remodeling and how they correlate with arterial remodeling
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D6in both LHF and in forms of PH with pre-capillary
predominance.
Are There Distinct Pathways in Vascular Cells in
Mild Versus Severe PH?
Although PH is deﬁned as a mean pulmonary arterial
pressure at right heart catheterization >25 mm Hg with
a normal pulmonary capillary wedge pressure, it is well
known that, on the basis of clinical and hemodynamic
ﬁndings, PH can range from mild to severe, even in the
presence of the same stimulus (e.g., hypoxia). This spectrum
of severity raises several critical pathogenetic and clinical
questions in terms of the distinctive features that differen-
tiate the severity stages.
Increased pulmonary artery pressures occur due to sus-
tained vasoconstriction, excessive pulmonary vascular
remodeling, and in situ thrombosis, which ultimately lead to
increased pulmonary vascular resistance. However, the
factors responsible for the aggravation or acceleration of PH
remain poorly deﬁned (Fig. 1). The contributing factors
likely involve accumulation of multiple events on a back-
ground of genetic predisposition. These factors involve the
action of vasoconstrictive and pro-remodeling processes,
including the action of inﬂammatory, procoagulant, anti-
apoptotic, and autoimmune mediators, cell–cell and cell–
matrix interactions, and environmental factors over time
(Fig. 2) (17). Although the pulmonary artery bed appears
unreactive to vasodilators in advanced disease, vasoreactivity
and remodeling possibly interact in disease evolution (18).
Whether the severity of pulmonary vascular disease
involves a constellation of pathobiological processes or is
deﬁned pathologically, with the hallmark ﬁnding of reduc-
tion of the pulmonary vascular lumen, remains unclear. The
deﬁnition of the severity of PH on the basis of histopath-
ological ﬁndings is complicated by the lack information on
what constitutes “normal.” Surprisingly, recent analysis ofFigure 1
Proposed Multifactorial Factors Inﬂuencing
Progression of Pulmonary Hypertension
In a suitable genetic background, the interplay of epigenetics and pathobiological
injurious events may amplify the severity of the disease, often associated with
more pronounced remodeling and worse clinical outcome.unused donor “control” lungs revealed substantial neointimal
formation, inﬂammation, and venous changes (15), features
usually judged to be “pathological.” This suggests a spectrum
from pristine vessels (which are observed primarily in the
younger controls) to vascular changes reminiscent of PH
that may be present as a function of normal aging, including
inﬂammation and left ventricular stiffening. Because
a description of the pathology in mild forms of PH is largely
unavailable, it is difﬁcult to discern whether the pathological
features we observe in “controls” are similar but still less
severe than in patients with “mild” PH. Perhaps a better
deﬁnition of severity would also incorporate the extent of the
reduction in cross-sectional area of the pulmonary vascular
bed. In this summary, we conﬁne our discussion of severity
to the extent of the pulmonary vascular remodeling process,
although in clinical practice, the assessment of severity will
also consider the function of the right ventricle. Below, we
expand on how genetic factors inﬂuence with cellular and
molecular pathogenetic processes to possibly account for the
severity of pulmonary vascular disease (Fig. 1).
Mutations in bone morphogenetic protein type II receptor
(BMPR2) or activin receptor-like kinase-1 (ALK-1) are
emerging as determinants of severity of PAH. Mutations in
BMPR2 (19) have been reported inmore than 70% of subjects
with 1 or more affected relatives (heritable PAH) and 11% to
40% of those with idiopathic PAH (20,21). Mutations in
several other genes have been found, including mutations in
the ALK1 gene (22), the endoglin gene (23), the SMAD9 gene
(24), the Caveolin-1 gene (25), and recently, the KCNK3
gene (26). Patients withBMPR2 orALK-1mutations present
with higher pulmonary vascular resistance (27). There is also
evidence that these patients present and die at a younger age
and with more severe disease compared with PAH patients
without mutations, and they are less likely to respond acutely
to vasodilators (28). Recent evidence suggests that the degree
of pulmonary vascular remodeling is greater in patients with
BMPR2 mutations compared with non-BMPR2–related
disease at the time of transplantation (4). In addition to these
causal rare sequence variants, variable expressivity of PAH
might be explained by genetic modiﬁers. For example, single
nucleotide polymorphisms in several genes, such as the
angiotensin-converting enzyme gene, the KCNA5 gene, the
serotonin transporter gene, and the serotonin 5-HT2B receptor
gene have been reported to inﬂuence disease penetrance or
progression. In addition, microsatellite instability of endo-
thelial cell growth and apoptosis genes within plexiform
lesions in idiopathic PAH (29), as well as somatic chromo-
some abnormalities (30), have been described. Most cases of
PH do not have known genetic triggers; moreover, vascular
cells isolated from experimental PH maintain their in vivo
characteristics when placed in culture, suggesting epigenetic
abnormalities. An example of such a contributing factor is the
silencing ofmitochondrial superoxide dismutase-2, which alters
redox signaling and, therefore, activates hypoxia inducible
factor (HIF)-1a, leading to the aerobic glycolysis seen in PH
(31,32). However, further studies, particularly focused on
Figure 2 Emerging Paradigms in PH Research
Research involving the broad effects of metabolic programming of intima and media pulmonary vascular cells (endothelial and smooth muscle cells) and the immediate per-
ivascular microenvironment. The perivascular region is dominated by ﬁbroblasts and migrating circulating cells, including inﬂammatory and progenitor cells. Shown in the center
is the impact of these factors in the intima and media of pulmonary arteries. The metabolic plasticity involves all cells involved in the pulmonary hypertension (PH) pan-
vasculopathy and is itself modiﬁed by inﬂammation and inﬁltrating progenitor cells (these paradigms are examined in more detail in Archer et al. [17]). Ca ¼ calcium; Th2 ¼
t-helper lymphocytes; Treg ¼ T regulatory cells.
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D7epigenetic control of additional key genes, are required to
verify their contribution to the pathogenesis of PH.
Apart from major effects of rare sequence variants in heri-
table forms of PAH, interindividual differences in response
to the same stimulus are well documented in subjects exposed
to environmental hypoxia at high altitude or in the context
of high pulmonary blood ﬂow or pulmonary venous hyper-
tension. This variable expressivity most certainly involves
the impact of unknown genetic inﬂuences regulating the
pulmonary vascular response; this variation in response to
hypoxia is also seen in different strains of rat (33) and bovines
exposed to high altitude (34). Elegant studies demonstrated
that this response is inherited (35), though the identiﬁcation
of the genetic basis is the subject of ongoing research (36).
The variable expressivity of PH might also be due to
exposure to different environmental inﬂuences or comor-
bidities including: inﬂammation, auto-immunity, viral
infection, and hormonal mediators. The speciﬁc topic of
inﬂammation is addressed in the following text. Further-
more, accumulating evidence indicates that metabolic dys-
function may also contribute to variability in susceptibility
and expressivity of PH (Fig. 2).
Although in general, animal models of PH do not recapit-
ulate the severe pathology of human disease, these experi-
mental models support the idea that PH can be triggered by
different stimuli and that the structural changes observed in the
pulmonary vasculature vary depending on the nature of the
injurious stimulus (37). Several studies have underlined the
importance of different signaling pathways in PH, including
elastase inhibitors (38), antagonists of epidermal growth factor
(4), or dietary copper restriction (39). The lack of animal model
ﬁdelity to the human pathology needs to be critically analyzed.
The obliterative changes in the most distal pre-capillaryarteries in the SU5416/hypoxia rat model (37,40), which
evolves over time (40), do not fully recapitulate the large
plexogenic lesions seen in patientsdits potential reversibility
may also indicate the model may not be fully reﬂective of the
largely irreversible nature of the human disease. Indeed, recent
studies indicate that the long telomeres present in mice may
limit the extent to which animal model can phenocopy
human disease.
Several genetic, molecular, biochemical, and environ-
mental factors may explain the variable expressivity of PH
and may contribute to its aggravation or acceleration. Severe
PAH seems to represent the far end of a spectrum, in which
there is an augmented burden of vascular injury and dysre-
gulated repair (Fig. 1). Further studies, which likely require
a “systems biology-like” approach, are needed to establish
which key signaling pathways in pulmonary vascular cells
lead to severe disease. Factors that contribute to this accel-
erated pathology include genetic abnormalities that may
affect: 1) the exuberance of the cellular response; 2) the
chronicity of an inﬂammatory stimulus; and 3) the severity
of the altered metabolic state and cumulative DNA damage.
What Are the Differences and Similarities Between
Cell Proliferations in PAH When Compared With
Traditional Neoplastic Disease?
The concept of a neoplastic-like pathobiology of PH (in
particular in PAH) (41) has its origins in the ﬁnding that
endothelial cells in IPAH plexiform lesions are clonal when
compared with similar lesions in lungs of patients with
congenital heart disease (42), coupled with somatic instability
in PAH lesions (29) and cultured lung endothelial cells (30).
Similar to the concept of an uncontrolled cell growth in PAH,
Tuder et al. JACC Vol. 62, No. 25, Suppl D, 2013
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D8early data emphasized the up-regulation of HIF-1a in plexi-
form lesions and pulmonary arteries in PAH (43) and survivin
in IPAH (44). These ﬁndings, largely centered on the angle of
disorganized cell growth, favored the emergence of an
apoptosis-resistant phenotype, a selection process that char-
acterizes neoplastic processes (45). In the past 8 years, further
experimental evidence emerged of metabolic plasticity and
altered cell energetics in the pathogenesis of PAH (46,47).
Metabolic reprogramming (Fig. 2), along with genomic
instability and mutations, immune escape, and cell-growth
promoting inﬂammation, is one of the so-called “emerging
hallmarks” pertinent to the pathogenesis of cancer (48). Recent
studies have delineated that cancer cells use these hallmarks as
driving forces leading to cell growth and co-option of the
surrounding stroma for their aggressiveness (49).
Supporting documentation of metabolic adaption of
pulmonary vascular cells derived from studies in rat smooth
muscle cells from the fawn-hooded model of PH (46) and
cultured human IPAH cells (31). In both experimental
settings, the hypertensive vascular cells would preferentially
use aerobic glycolysis (instead of mitochondrial metabolism).
The preferential use of aerobic glycolysis by proliferating
cells (including cancer cells) would endow a selective growth
advantage to pulmonary vascular cells: glucose and glycolytic
intermediates provide key substrates for the pentose phos-
phate shunt to generate reducing equivalents in the form of
reduced nicotinamide adenine dinucleotide phosphate and
nucleotides, essential for cell growth (50).
The preferential utilization of aerobic glycolysis appears to be
related toup-regulation of several glycolytic genes and increased
expression of the subunit 4.2 of cytochrome oxidase in the
mitochondrial respiratory chain, all events driven by expression
of HIF-1a (51). In human PAH lungs, HIF-1a appears to be
expressed by endothelial cells (43) and smooth muscle cells
(46). The source of stabilization of HIF-1a remains unclear,
but it appears to be related to altered cellular oxidant/antioxi-
dant balance (46,52) present in hypertensive cells. Moreover,
HIF-1a could also account for the increased mobilization of
hematopoietic precursors in PAH (53–55), which might
promote further injury to the pulmonary endothelium (13) and
possibly to contribute to the remodeled cell population (Fig. 2).
In addition to playing roles in the metabolic adaption and
mobilization of bone marrow precursors, HIF-1a also
participates in the regulation of mitochondria dynamics.
HIF-1a accounted for decreased numbers of mitochondria
and decreased nitric oxide availability in IPAH cells when
compared with control cells (43); of interest, these alter-
ations also correlate with increased IPAH endothelial cell
proliferation when compared with normal endothelial cells
in culture (56). HIF-1a–dependent mitochondria plasticity
also pertains to PH smooth muscle cells. Activation of HIF-
1a activity with cobalt or desferrioxamine leads to mito-
chondria ﬁssion (mediated by activation of dynamin related
protein-1) in human PAH and rodent PH smooth muscle
cells; this is driven by activation of dynamin-related protein-1
by active cyclin B1 (57). Finally, consistent with the role ofmitochondria ﬁssion in PH smooth muscle cell growth,
inhibition of dynamin-related protein-1 with the peptide
Mdiv-1 blocks cell proliferation in cultured cells as well as
PH caused by in vivo administration of cobalt and chronic
hypoxia (57). Conversely, overexpression of mitofusin-1,
which leads to mitochondria fusion, counteracts the mito-
chondria phenotype in PH smooth muscle cells (58).
The paradigm of metabolic plasticity and adaption of PH
cells has wider implications, interfacing with controls of
cellular stresses and protein misfolding and protein sorting in
cytoplasmic compartments (59). In line with these paradigms,
there is evidence of an altered endoplasmic reticulum (ER)
stress response in PH (60), whichmay ultimately contribute to
both adverse remodeling and elevation of pulmonary artery
pressures (61). Moreover, ER stress can lead to activation of
the stress-related kinase activating transcription factor-6,
which increases the expression of Nogo-B. This contributes
to an abnormal distancing and signaling coupling (via calcium
ﬂuxes) between the ER and the mitochondria (62). These
events would lead to an increase in glycolysis, favoring
vascular cell proliferation and ultimately PH.
The inroadsmade by themetabolic-related studies inPHare
starting to bear translational fruits. There is increasedmetabolic
labeling of glucose uptake with 18-ﬂuorodeoxyglucose of
IPAH lungs and right ventricle when compared with controls
(31,63), which has also been observed in animal models of PH
(64,65). Pharmacologic targeting of the preferential use of
glycolysis by PH cells is being tested in humans with the small
molecule dichloroacetate (NCT01083524), which improves
PH in animals by blocking pyruvate dehydrogenase kinase,
a negative regulator of pyruvate import into the mitochondria
(66).
We are at the beginning of deciphering the role of cellular
metabolism in the pathogenesis of PH and how this
fundamental process relates to inﬂammation, remodeling,
therapeutic response, and so on. Genetic modiﬁcations that
favor glycolysis in multiplying cells would certainly
contribute to part of the process of remodeling. However,
many of the vascular cells in established human PH are
quiescent, long-lived, and probably resistant to apoptosis.
These quiescent cells would have substantially different
metabolic requirements from those of proliferating cells.
Clarifying this metabolic heterogeneity and how it contrib-
utes to remodeling and vasoconstriction will be critical
moving forward. The interface of cell metabolism with the
genetic basis of PAH and inﬂammation will certainly
constitute key areas of future investigation.
What Is the Role of Inﬂammation in the Initiation
and Progression of Different PAH Types?
Inﬂammation has been long recognized as an important
pathogenetic element in PH (67). Expanding on prior
observations of accumulation of inﬂammatory cells in PAH,
it was documented for the ﬁrst time that the amount of
perivascular inﬂammatory inﬁltrate, largely of lymphocytes,
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D9correlated with parameters of pulmonary vascular remodel-
ing and hemodynamics in PAH (15). Inﬂammation consists
of a complex series of interactions among soluble factors and
immunologically specialized cells triggered in response to
traumatic, infectious, post-ischemic, toxic, or autoimmune
injury (68). It is increasingly clear that early and persistent
inﬂammation is present and contributes to pulmonary
vascular disease, as documented in tissue-based studies and
studies of circulating inﬂammatory cells and chemical
mediators.
The presence of elevated levels of circulating inﬂamma-
tory cytokines, such as interleukin-1a, in PAH is well
recognized (69). More recently, a wide range of cytokines
has been shown to be elevated and to correlate with surviv-
al in PAH (70). At the tissue level, traditional cellular
components of inﬂammation are described in the hyperten-
sive pulmonary circulation (71,72). More speciﬁcally, cellular
inﬂammation involves increases in the number of peri-
vascular macrophages (CD68þ), macrophages/monocytes
(CD14þ), mast cells, dendritic cells (DCs) (CD209þ),
T cells (CD3þ), cytotoxic T cells (CD8þ), and helper
T cells (CD4þ) in the walls of PAH vessels compared with
control subjects (73). FoxP3(þ) cells have been shown to be
signiﬁcantly decreased, suggesting a reduction in the local
number of T regulatory (Treg) cells (73). Although increased
numbers of circulating Treg cells has been reported in
patients with idiopathic PAH (74,75), the reduced numbers
of Treg in lung tissue may reﬂect decreased tissue recruit-
ment of these cells. Given their immune soothing role,
a diminished negative regulation on other active immune/
inﬂammatory cells may trigger or amplify pulmonary vascular
remodeling and PH.
The innate inﬂammatory system appears to also partici-
pate in PAH. Natural killer cells, which target stressed,
virally infected, or oncogenically transformed cells inde-
pendent of antigen recognition, are dysfunctional, with
reduced number and cytolytic capacity, in patients with
idiopathic PAH and in mouse and rat models of PH (76).
Neutrophils may have potentially unrecognized roles as
sources of powerful proteases, including elastases, which
have recognized roles in pulmonary vascular remodeling
(38,77). Because hypoxia exerts profound effects on
neutrophil function (e.g., resistance to apoptosis [78]),
further evaluation of the role of the neutrophil in PAH is
overdue. The complement system, which bridges innate and
adaptive immunity, is also activated in PAH, and deﬁciency
of complement C3 protects mice from hypoxia-induced PH
(79). Mechanistic studies focusing on the innate immune
system are needed for a better appreciation of its role in PH.
However, recent insights highlighted a potential role
for acquired immunity, suggesting that the pathogenesis
of PH may involve speciﬁc and targeted immune cellular
responses. A recent study identiﬁed a large number of
tertiary lymphoid follicles in lungs from patients with
idiopathic PAH when compared with control lungs (80).
These lymphoid follicles in idiopathic PAH patientsdisplayed the canonical cellularity and structure of bona ﬁde
tertiary follicles, whereas lymphoid organogenic chemo-
kines, such as CXCL13 and CCL19/CCL21, were over-
expressed. These data provide a structural basis for a local
autoimmune response in this disease (81–83). Finally,
inﬂammation is closely associated with pulmonary vascular
disease in the setting of autoimmune diseases, such as
scleroderma, and paradigmatic of the interplay of inﬂam-
mation and PH is its link with the infection with the
parasite Schistosoma mansoni (the most frequent cause of
PAH worldwide [84]) and human immunodeﬁciency virus
infection (85).
Vascular inﬂammation in general and PH in particular has
traditionally been considered an “inside-out” response
centered on leukocyte/monocyte recruitment to the intima of
blood vessels driven by the endothelium-expressed adhesion
molecules. Growing experimental evidence, however,
supports an alternative paradigm of an “outside-in” hypoth-
esis, in which vascular inﬂammation is initiated in the
adventitia and progresses inward toward the media and
intima, coupled with the activation of the remodeling process.
In support of the “outside-in” hypothesis of adventitial regu-
lation of inﬂammation are observations that, in a wide variety
of vascular injuries, including PH, there is a rapid inﬂux of
leukocytes into the adventitial compartment (86). The
immediate perivascular environment in PH becomes popu-
lated by inﬂammatory/progenitor cells, in a niche dominated
by adventitia ﬁbroblasts (37,71,86–90). These adventitial
ﬁbroblasts and recruited monocytes, particularly under
hypoxia, express in a time-dependent and pulmonary artery–
speciﬁcmanner several cytokines/chemokines, their receptors,
and adhesion molecules; these cells, therefore, appear to
initiate and perpetuate the inﬂammatory response in an
“outside-in” fashion, possibly mediated by nuclear factor
kappa B signaling (91,92). Therefore, temporal-spatial dys-
regulation and/or failure in the normal “switch-off signal” in
ﬁbroblasts and/or macrophages/DCs may directly contribute
to the persistence of a chronic inﬂammatory immune
response. These adventitia processes are more evident in
nonmouse models and in the lungs of patients with PH,
possibly due to the presence of bronchial circulation.
The action of secreted cytokines, including TGF-b, in the
adventitia mediates speciﬁc homing for leukocytes in this
vascular compartment, leading to their inappropriate/path-
ologic retention and survival (92). These homing/recruit-
ment cytokines include up-regulated adhesion molecules,
including intercellular adhesion molecule 1 and vascular
adhesion molecule-1, and stromal derived factor-1/CXCR4,
which promotes adhesion of leukocytes and bone marrow
precursor cells, respectively. The adventitia is, therefore,
suited to harbor canonical innate immune cells, speciﬁcally
macrophages and DCs, which with adventitial ﬁbroblasts,
are all equipped with the necessary machinery (e.g., toll-like
receptors and inﬂammasome components [like the nod-like
receptors]) to potently respond to a variety of exogenous and
endogenous danger signals.
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D10Importantly, there is growing evidence that epigenetic
marks may “lock” innate immune cells into a distinct func-
tional phenotype, with loss of functional plasticity and
failure to respond to regulatory signals. The inﬂammatory
microenvironment in the pulmonary circulation promotes
epigenetic marks in macrophages, locking their functional
phenotype into a pro-ﬁbrogenic and pro-remodeling
macrophage (93–97). Different signaling processes, medi-
ated largely by signal transducers and activators of tran-
scription 1, 3, and 6, may drive macrophage-promoted
remodeling (98); it is likely that all of these macrophages are
present in PH and play complex and time-dependent,
sometimes overlapping or dedicated, roles in the disease.
Moreover, it is also likely that individual macrophages are
plastic, changing their function and signaling according to
the disease stage and speciﬁc molecular triggers.
Finally, emerging concepts involve the potential of organ-
speciﬁc microbiota and their metabolic products to engage
the inﬂammasome pathways and to inﬂuence pulmonary
vascular responses, as shown in the liver (99). A further
pathway by which remote signaling might target the
pulmonary vasculature is by the release of cell-derived exo-
somes from distant sources, exerting anti- or pro-
inﬂammatory depending on their cargo. Exosomes derived
from mesenchymal stem cells were found to inhibit the
hypoxic activation of the signal transducers and activators of
transcription 3 pathway in hypoxic mice and prevent the
development of PH (100).
Conclusions
Cytokines and immune cells appear to play signiﬁcant but
complex roles in the initiation and progression of PH. Major
unanswered questions include:
1. What determines the abnormal host response to
inﬂammation that leads to the initiation and
progression of PH?
2. Is the inﬂammatory response in PAH caused by
autoimmunity or infection?
3. Which speciﬁc features of the inﬂammatory response
can be enhanced (if protective) or blocked (if detri-
mental) for therapeutic intervention?Reprint requests and correspondence: Dr. Rubin M. Tuder,
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